The use of cannabis and cannabinoid products for the treatment of neuropathic pain is a growing area of research. This type of pain has a high prevalence, limited response to available therapies and high social and economic costs. Systemic cannabinoid-based therapies have shown some unwanted side effects. Alternative routes of administration in the treatment of neuropathic pain may provide better acceptance for the treatment of multiple pathologies associated with neuropathic pain. To examine the efficacy, tolerability, and safety of cannabinoids (individualized formulations, phytocannabinoids, and synthetics) administered by routes other than oral or inhalation compared to placebo and/or conventional medications in the management of neuropathic pain. This systematic review of the literature reveals a lack of clinical research investigating cannabis by routes other than oral and inhalation as a potential treatment for neuropathic pain and highlights the need for further investigation with well-designed clinical trials. There is a significant lack of evidence indicating that cannabinoids administered by routes other than oral or inhaled may be an effective alternative, with better tolerance and safety in the treatment of neuropathic pain. Higher quality, long-term, randomized controlled trials are needed to examine whether cannabinoids administered by routes other than inhalation and oral routes may have a role in the treatment of neuropathic pain.

Cannabis has been widely used as a medicinal plant for millennia; however, studies related to its main components were first conducted in 1960. Subsequently, laboratories have produced new components and structures related to its active biological properties. Countries that have approved the medicinal use of cannabis impose regulations that govern its clinical and scientific use. One means of administering medicinal cannabis is via a magistral preparation that must have a medical prescription and be prepared in an establishment that meets quality standards to ensure the quantities of its main components, such as tetrahydrocannabinol (THC) and cannabidiol (CBD). Furthermore, suppliers must have a clear indication of its use in the patient before prescription. This review shows the published evidence regarding the clinical use of medicinal cannabis magistral preparations in the management of post-chemotherapy nausea and vomiting, neuropathic pain in multiple sclerosis, and anorexia and cachexia in patients with HIV.

Existe un incremento en la prevalencia de enfermedades neurológicas y su carga de enfermedad. Debido a ello, identificar la frecuencia de síntomas y las alteraciones funcionales es de vital importancia para definir un adecuado plan de tratamiento. Se llevó a cabo un estudio de corte transversal para identificar los síntomas principales y las alteraciones funcionales en pacientes neurológicos de un centro de referencia colombiano para manejo de rehabilitación. Se encontraron como síntomas y alteraciones funcionales más frecuentes: alteraciones de la marcha (65,5%), desórdenes de comunicación (36,98%), alteraciones emocionales y de memoria (38%), dolor (29,45%) y alteraciones en las actividades básicas cotidianas (24,3%). El 50% de los pacientes que reportaron dolor, el 30% de los que manifestaron insomnio y el 80% de los que refirieron estreñimiento no recibieron tratamiento en la primera consulta. Algunos de los síntomas identificados no son características que definen la enfermedad, y no siempre son objeto de intervención. Los resultados de este estudio pueden contribuir a reconocer la carga de los síntomas de las enfermedades neurológicas, sensibilizando a los profesionales de la salud acerca de la importancia del cuidado paliativo en pacientes con enfermedades progresivas no oncológicas.

This study examines the effect of microfluidization on the physicochemical properties, stability, release behavior, and cytocompatibility of cannabidiol (CBD) nanoemulsions intended for topical application. CBD is a non-psychoactive cannabinoid characterized by anti-inflammatory and analgesic activity; however, its therapeutic use is limited by low solubility and poor bioavailability. To address these limitations, nanoemulsions were formulated using avocado oil and Tween 80 and optimized through a Box–Behnken experimental design evaluating microfluidization pressure (5000–20,000 PSI), CBD concentration (0–2%), and oil content (8–10%). Nanoemulsions were characterized over a 60-day period in terms of droplet size, dispersity index (D), and zeta potential. An increase in processing pressure led to a reduction in both droplet size and dispersity, with optimal conditions identified between 11,000 and 15,000 PSI. Higher oil and CBD concentrations were associated with an increase in the magnitude of the zeta potential, contributing to electrostatic stabilization of the system. Encapsulation efficiency reached approximately 81.4%. Cell viability assays in HaCaT keratinocytes indicated no significant cytotoxic effects. The optimized formulation exhibited a sigmoidal CBD release profile best described by Weibull and Gompertz models (R² ≈ 0.99), suggesting combined diffusion and interfacial mechanisms that support efficient topical delivery.

Background: The management of sedative and analgesic infusions in intensive care units (ICUs) represents a global clinical challenge. Clinical decision support systems (CDSSs) have emerged as an approach to facilitate protocol standardization and mitigate adverse effects associated with prolonged sedation and analgesia. Objective: To evaluate the usability and technical quality of UCISAB, a CDSS designed to optimize sedoanalgesia in the ICU. Methods: A multicenter, cross-sectional, mixed-methods usability evaluation was conducted. A prototype was evaluated using the System Usability Scale (SUS) and the User Mobile Application Rating Scale (uMARS), complemented by a qualitative analysis of open-ended comments. Results: A total of 31 physicians participated (attending physicians and residents). The mean SUS usability score was 66.13 (SD ±21.26), categorized as “Marginal High.” On the uMARS, the median scores were 4.28 for objective quality (good), 3.75 for subjective quality (acceptable), and 4.33 for impact (good). The stated willingness to apply the tool’s recommendations in clinical practice reached 93.5%, with a median intention-to-use score (uMARS) of 4.0 (good). Exploratory analysis revealed no significant difference in SUS scores between residents and attending physicians (p = 0.072). In these exploratory comparisons, statistically significant differences by professional role were found only in the uMARS dimensions: objective quality (p < 0.001), subjective quality (p = 0.023), and impact (p = 0.036). Qualitative feedback suggested that the tab-based architecture may increase cognitive load among expert users, highlighting a need for interface simplification. Conclusions: UCISAB showed favorable perceived quality and a high stated willingness to use, while usability remained marginal; further interface and pharmacological refinements, together with prospective clinical validation in real-world settings, are required before routine implementation. Professional role may influence perceived quality, suggesting the potential value of adaptive interface designs; however, this association requires confirmation in future studies. Developing systems that optimize sedation and analgesia in critical care remains an unmet need in ICUs.